About Us
Horizon Holdings is a publicly-traded biosciences company with an innovative and patent-protected Direct-In-Plant, Psychedelic, and Medicine discovery platform; using our platform, we discover and develop novel genes that have beneficial effects on plants, such as yield enhancement, drought resistance, and herbicide and insect tolerance. Our genes are licensed to major seed and crop protection companies. Horizon Holdings Biosciences' revolutionary gene-editing technology is both a critical enabler and a stand-alone therapeutic modality. It will significantly accelerate the development of transformative therapies for patients and will bolster the company's newly established cell and gene therapy platform.
Horizon Holdings' platform enables the simultaneous and massive scanning of millions of genes directly on plants and mushrooms, making gene discovery more effective and efficient than ever before. By leveraging our platform, we can now address any gene pool from any source and test millions of genes directly in planta, allowing us to select the best-performing plants and mushrooms for any trait. For instance, we collected soil samples from the desert to identify the best genes for plant drought resistance. Following the gene discovery stage, we use genetic modification, gene editing, and RNAi technologies to improve seeds and fungi, as well as external applications (RNAi sprays) for yield enhancement and crop protection.
Horizon Holdings' platform enables us to unleash the full potential of our cell and gene therapy strategy by combining novel CRISPR systems with our existing gene augmentation and induced pluripotent stem cell (iPSC) platforms.
"Partnering with Horizon Holdings' cutting-edge scientific team is critical to our company's mission of improving the lives of patients suffering from agricultural and medical conditions that are currently intractable."